Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma

Trial Details

NCT ID
NCT05462613
Phase
PHASE2 / PHASE3
Sponsor
Centre Hospitalier Universitaire de Besancon
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • quality of life questionnaires
  • Blood sample
  • Regorafenib
  • Metronomic chemotherapies
  • Aspirin
  • Bevacizumab
Locations (sample)
  • Besançon, France|47.24878,6.01815
  • Clermont-Ferrand, France|45.77969,3.08682
  • Créteil, France|48.79266,2.46569
  • Dijon, France|47.31344,5.01391
  • Lyon, France|45.74906,4.84789

Key Eligibility Criteria

  • Patients with histologically proven metastatic colorectal cancer in progression after a first line of chemotherapy +/- targeted therapy
  • Patients must have been treated for their metastatic disease with one of the following regimens as first-line therapy:
  • FOLFOX (Oxaliplatine, 5-Fluoro-uracil)
  • FOLFIRI (Irinotecan, 5-Fluoro-uracil)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →